The second exit in under a year follows controversy around CRLs for Replimune and Capricor, including criticism that mid- and ...

In a conversation with Pharmaceutical Executive Ron Lanton, Senior Partner & Global Strategist, Lanton, Lanton & Sosa Law ...

David Rosner, principal and global life sciences customer engagement leader at Deloitte, spoke with Pharmaceutical Executive ...

Based on the clinical trial findings, Ipsen is withdrawing Tazverik across all indications, including both follicular lymphoma and epithelioid sarcoma, and is discontinuing all active tazemetostat ...

GSK will receive $300 million upfront from Alfasigma for linerixibat, plus $100 million upon anticipated FDA approval and additional regulatory and sales-based milestones with tiered double-digit ...

FDA approved Tecvayli (teclistamab-cqyv), a Johnson & Johnson drug developed for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) who have received at least one of line of ...

While regulatory alignment remains essential, operational urgency driving companies to AI adoption is equally profound. In ...

Market access strategies are evolving as more biopharma companies commercialize their own therapies, requiring closer ...

Employer Connect aggregates diverse administrators, from basic benefits management to comprehensive obesity programs with wraparound services, enabling employers to tailor coverage models to workforce ...

Series C proceeds position Spectris for pivotal top-line data, regulatory submission, and launch planning ahead of a targeted ...

A $400 million, four-year Blackstone Life Sciences financing supports ongoing and future duvakitug development, with ...

In today’s Pharmaceutical Executive Daily, Cognito Therapeutics and Nexcure secure new financing rounds to advance their pipelines, artificial intelligence and large language models reshape ...